The 4 most recent market catalysts affecting $AVLN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 2, 2026
Corporate Catalyst
Neutral
Impact 65
Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60
Raymond James analyst Tiago Fauth initiated coverage on Avalyn Pharma (AVLN) with an 'Outperform' rating and a $60 price target. This event is significant for AVLN as it introduces…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 65
Avalyn Pharma Reports New Data Showing Predicted Aerosol Distribution Of AP01 And Survey Data Highlighting Patient Perspectives On Participation In Clinical Studies For Idiopathic Pulmonary Fibrosis
Avalyn Pharma presented new data at a major medical conference, showing that its inhaled therapy AP01 is predicted to distribute effectively in the lungs, even in severe disease. T…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57
Morgan Stanley analyst Judah Frommer maintained an 'Overweight' rating on Avalyn Pharma (AVLN) and raised the price target from $53 to $57. This action signals a continued positive…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 92
Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate
Avalyn Pharma (AVLN) announced Q2 earnings per share of $(0.65), which was substantially below the analyst consensus estimate of $(0.53). This 22.64% miss indicates that the compan…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.